Physician profile
Patrick J Troy
NPI 1033255229
$385,378.58
in general payments reported to CMS, 2019-2025
39 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $24K · 2021: $56K · 2022: $79K · 2023: $58K · 2024: $60K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Travel and Lodging: $17K · Consulting Fee: $17K · Food and Beverage: $13K · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,462.50 |
| Travel and Lodging | $17,229.14 |
| Consulting Fee | $17,203.13 |
| Food and Beverage | $12,851.19 |
| Education | $237.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $245,733.95 | 2019-2025 | Ekosonic, General - Therapies, Clinical Trial Product |
| Ekos Corporation | $44,540.45 | 2019 | |
| Baxter Healthcare | $38,852.95 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $29,949.63 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Jazz Pharmaceuticals INC. | $12,488.05 | 2019-2025 | |
| Amgen INC. | $4,236.14 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $3,028.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Access Vascular INC | $2,238.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.39 | 2019-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $531.68 | 2021-2025 | Wakix |
| Mylan Specialty L.P. | $388.39 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $339.75 | 2022-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $314.48 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $309.70 | 2019-2025 | Dupixent |
| Verona Pharma, INC. | $219.52 | 2025 | Ohtuvayre |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Troy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.